Indian corporate and IPO market activity

The Indian corporate and equity markets have seen significant activity driven by a surge in initial public offerings (IPOs) and major corporate expansions.

In early September 2026, a rush of companies sought to list on exchanges, with potential capital raises reaching up to Rs 25,000 crore. This trend was influenced by the upcoming expiry of SEBI regulatory approvals and the onset of the Pitru Paksha period. Notable participants included LCC Projects Limited, Rentomojo, Manipal Payments & ID Solutions, and Karamtara Engineering.

By late September, investor attention shifted toward broader corporate developments. These included Airtel Money’s plans to list on the London Stock Exchange, significant dividend payouts from NTPC, and the commissioning of a lithium-ion cell manufacturing facility by Exide Energy Solutions. Other developments involved HCL Technologies securing IT modernization contracts, infrastructure orders for SUGS Lloyd, and various stock actions from Adani Group, JSW Dulux, and Ola Electric Mobility.

Recent activity in late September has highlighted further expansion in the pharmaceutical and technology sectors. Claroid Pharmaceuticals Limited filed a Draft Red Herring Prospectus with SEBI for an IPO intended to fund a new manufacturing facility for injectables. Within the same sector, Natco Pharma approved a rights issue to raise up to Rs 1,279.35 crore. Additionally, Dr Lal PathLabs moved to enhance its genomics expertise by approving the acquisition of a 70 percent stake in Gujarat-based SN Genelab for approximately Rs 168 crore. In the technology space, Genesys International Corporation secured a Rs 283 crore World Bank-funded contract to develop a 3D digital map platform for Ahmedabad.